Insider Selling: United Therapeutics Corporation (UTHR) CEO Sells $149,792.76 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,269 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $118.04, for a total transaction of $149,792.76. Following the sale, the chief executive officer now directly owns 1,409 shares in the company, valued at approximately $166,318.36. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

United Therapeutics Corporation (NASDAQ UTHR) opened at $120.95 on Friday. United Therapeutics Corporation has a twelve month low of $112.01 and a twelve month high of $169.89. The company has a market cap of $5,226.37, a price-to-earnings ratio of 10.67 and a beta of 1.38.

United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The company had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same quarter last year, the firm earned $4.23 EPS. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. equities analysts predict that United Therapeutics Corporation will post 11.92 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/05/insider-selling-united-therapeutics-corporation-uthr-ceo-sells-149792-76-in-stock.html.

Several hedge funds have recently added to or reduced their stakes in the stock. HPM Partners LLC grew its holdings in shares of United Therapeutics Corporation by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 15 shares during the last quarter. First Allied Advisory Services Inc. grew its holdings in shares of United Therapeutics Corporation by 0.4% during the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 19 shares during the last quarter. Nomura Asset Management Co. Ltd. grew its holdings in shares of United Therapeutics Corporation by 0.3% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock valued at $1,712,000 after purchasing an additional 40 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of United Therapeutics Corporation by 1.4% during the 2nd quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 45 shares during the last quarter. Finally, Synovus Financial Corp grew its holdings in shares of United Therapeutics Corporation by 1.2% during the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock valued at $731,000 after purchasing an additional 69 shares during the last quarter.

A number of research firms recently weighed in on UTHR. Zacks Investment Research lowered shares of United Therapeutics Corporation from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 3rd. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a report on Friday, July 14th. TheStreet lowered shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. Cowen and Company reissued a “hold” rating and issued a $129.00 price target on shares of United Therapeutics Corporation in a report on Friday, October 27th. Finally, HC Wainwright reissued a “hold” rating and issued a $95.00 price target on shares of United Therapeutics Corporation in a report on Thursday, October 26th. Five analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. United Therapeutics Corporation has a consensus rating of “Hold” and an average price target of $132.82.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit